How Quitting Alcohol Changes the Brain and Increases Relapse Risk

<>

Neural Activity and the BNST Brain Region

Researchers monitoring brain activity during abstinence focused on a small collection of cells located deep near the center of the brain known as the bed nucleus of the stria terminalis, or BNST. According to the study findings, scientists previously linked this specific structure to symptoms of anxiety and depression associated with alcohol use disorder.

When investigators allowed abstinent mice to reenter an environment where alcohol was previously available, the animals attempted to drink from spouts containing only water. These retrieval attempts correlated directly with activity in the BNST region. Furthermore, mice that developed an aversion-resistant taste for heavily bitter alcohol showed more than double the activity in this brain area compared to subjects that did not experience forced abstinence.

Implications for Relapse Risk and Screening

Crucially, researchers observed heightened activity in the BNST even prior to giving abstinent subjects access to bitter alcohol solutions. According to the study authors, this early neural activation suggests it may eventually become possible to identify individuals at higher risk of relapse by screening for BNST activity patterns when exposure to alcohol triggers occur.

While health authorities emphasize that abstaining from alcohol generally improves overall health outcomes, addiction researchers have long theorized that physiological adaptations during abstinence contribute significantly to relapse vulnerabilities. The new mouse studies provide concrete behavioral and neurological evidence connecting forced abstinence to aversion-resistant alcohol intake, where subjects consume larger quantities despite unappealing bitter additives like quinine.

Public Health Context of Alcohol Misuse

Alcohol misuse remains a primary public health challenge in the United States, where over 80 percent of Americans aged 12 and older consume alcohol at some point in their lives, according to public health data. Approximately 10 percent of those individuals eventually experience alcohol use disorder, translating to nearly 30 million people who need clinical intervention.

Despite the availability of several Food and Drug Administration-approved treatments, the number of diagnosed cases in the United States has effectively doubled since 1999. Clinicians often remain ill-equipped to predict which patients will face the highest hurdles in maintaining sobriety, leaving researchers searching for reliable biomarkers and screening mechanisms to improve long-term treatment strategies.